Gastroenterology

Biosimilars and the Nocebo Effect

October 18th 2017

By Jackie Syrop

Switching patients from originator biologics to biosimilars is associated with the potential for a “nocebo” effect, a phenomenon that occurs when a patient’s negative expectation causes a treatment to have a more negative effect than it otherwise would—essentially, the opposite of the placebo effect.

Consensus Statements Support TDM-Guided Anti-TNF Therapy in IBD

October 17th 2017

By Jackie Syrop

Article

Anti–tumor necrosis factor drugs are expensive, and there are a limited number of choices for IBD treatment, highlighting the need to use every existing agent optimally.

Biosimilars Face Challenges From Providers, Patients, and Policies

October 13th 2017

By Kelly Davio

Article

In recent paper published in Rheumatology, authors Till Uhlig, MD, and Guro L. Goll, PhD explore some of the remaining barriers to the adoption of biosimilar therapies in Europe. Physician attitudes, patient concerns, and prescribing restrictions on biologic therapies are all identified in the paper as having a role curbing uptake of biosimilars.

Study Finds Biologics Improve Outcomes in IBD, Are Cost Ineffective

October 12th 2017

By Jackie Syrop

Article

A recent study found that, while biologic agents improved outcomes in patients with inflammatory bowel disease, they incurred such high costs that they were deemed cost ineffective, particularly for use as maintenance therapy.

Disparities in Access to Biologics for Crohn's Disease in Europe Associated With GDP

October 12th 2017

By Jackie Syrop

Article

The number of patients with Crohn’s disease who receive biologic therapy is strongly correlated with the gross domestic product in 10 European countries, according to a recent analysis.

CT-P13 Safe, Cost Effective in Treating Pediatric IBD

October 9th 2017

By The Center for Biosimilars Staff

Article

A study newly published in Archives of Disease in Childhood sought to develop much-needed data specific to the treatment of pediatric inflammatory bowel disease with biosimilar infliximab, with a focus on safety and effectiveness.

No Significant Differences in AEs in Patients Receiving Infliximab, Adalimumab for Crohn's Disease

October 2nd 2017

By Jackie Syrop

Article

A Brazilian study reports that adverse events occurred in approximately two thirds of patients with Crohn’s disease who were taking the anti-tumor necrosis factor medications infliximab and adalimumab.

AbbVie Reaches Settlement With Amgen Over Amgevita

September 28th 2017

By Kelly Davio

Article

Drug maker Amgen announced today that it has reached a global settlement with AbbVie, developer of reference adalimumab (Humira), over Amgen’s biosimilar adalimumab, Amgevita.

Study Shows Patients With Ulcerative Colitis Prefer Adalimumab to Infliximab

September 27th 2017

By Jackie Syrop

Article

A study of Japanese patients with ulcerative colitis who were naïve to anti–tumor necrosis factor treatment found that patients preferred adalimumab to infliximab, but the researchers also reported no differences in the efficacy of the 2 treatments.

Infographic: The 7 FDA-Approved Biosimilars

September 24th 2017

By The Center for Biosimilars Staff

Article

The FDA has approved, to date, 7 biosimilar treatments.